Design of next-generation protein therapeutics - PubMed (original) (raw)
Review
Design of next-generation protein therapeutics
Justin Caravella et al. Curr Opin Chem Biol. 2010 Aug.
Abstract
Since the first protein therapeutics were approved two decades ago, the field has seen a transition from the development of naturally occurring proteins to design of molecules engineered for optimal target recognition, pharmacokinetics, biodistribution, and therapeutic function. Many modified antibodies and monovalent or multispecific antibody-like molecules with custom profiles are in different stages of drug development. In addition, several non-antibody protein scaffolds that interrogate a broad range of targets are being pursued. As protein engineering efforts have expanded and diversified, it has become increasingly important to understand the biophysical and biochemical properties of proteins and to translate this knowledge into design of optimized pharmaceutical agents.
2010 Elsevier Ltd. All rights reserved.
Similar articles
- Engineered protein scaffolds as next-generation antibody therapeutics.
Gebauer M, Skerra A. Gebauer M, et al. Curr Opin Chem Biol. 2009 Jun;13(3):245-55. doi: 10.1016/j.cbpa.2009.04.627. Epub 2009 Jun 6. Curr Opin Chem Biol. 2009. PMID: 19501012 Review. - Molecular engineering and design of therapeutic antibodies.
Presta LG. Presta LG. Curr Opin Immunol. 2008 Aug;20(4):460-70. doi: 10.1016/j.coi.2008.06.012. Curr Opin Immunol. 2008. PMID: 18656541 Review. - Creating the next generation of protein therapeutics through rational drug design.
Szymkowski DE. Szymkowski DE. Curr Opin Drug Discov Devel. 2005 Sep;8(5):590-600. Curr Opin Drug Discov Devel. 2005. PMID: 16159021 Review. - Introduction to current and future protein therapeutics: a protein engineering perspective.
Carter PJ. Carter PJ. Exp Cell Res. 2011 May 15;317(9):1261-9. doi: 10.1016/j.yexcr.2011.02.013. Epub 2011 Mar 1. Exp Cell Res. 2011. PMID: 21371474 Review. - Antibody engineering and modification technologies.
Filpula D. Filpula D. Biomol Eng. 2007 Jun;24(2):201-15. doi: 10.1016/j.bioeng.2007.03.004. Epub 2007 Mar 31. Biomol Eng. 2007. PMID: 17466589 Review.
Cited by
- Natural products: a continuing source of novel drug leads.
Cragg GM, Newman DJ. Cragg GM, et al. Biochim Biophys Acta. 2013 Jun;1830(6):3670-95. doi: 10.1016/j.bbagen.2013.02.008. Epub 2013 Feb 18. Biochim Biophys Acta. 2013. PMID: 23428572 Free PMC article. Review. - Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins.
Liu B, Singh K, Gong S, Canakci M, Osborne BA, Thayumanavan S. Liu B, et al. Angew Chem Int Ed Engl. 2021 Jun 1;60(23):12813-12818. doi: 10.1002/anie.202103106. Epub 2021 May 5. Angew Chem Int Ed Engl. 2021. PMID: 33768625 Free PMC article. - Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.
Winkler J. Winkler J. Ther Deliv. 2011 Jul;2(7):891-905. doi: 10.4155/tde.11.56. Ther Deliv. 2011. PMID: 22318893 Free PMC article. Review. - A High-Throughput Platform for the Generation of Synthetic Ab Clones by Single-Strand Site-Directed Mutagenesis.
Gallo E. Gallo E. Mol Biotechnol. 2019 Jun;61(6):410-420. doi: 10.1007/s12033-019-00171-9. Mol Biotechnol. 2019. PMID: 30963479 - Assessment of the evolution of cancer treatment therapies.
Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández A. Arruebo M, et al. Cancers (Basel). 2011 Aug 12;3(3):3279-330. doi: 10.3390/cancers3033279. Cancers (Basel). 2011. PMID: 24212956 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials